Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. More Details
+ 3 more risks
Excellent balance sheet with limited growth.
Share Price & News
How has Xenetic Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: XBIO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: XBIO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: XBIO underperformed the US Biotechs industry which returned 26.3% over the past year.
Return vs Market: XBIO underperformed the US Market which returned 22.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Xenetic Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StHere's Why We Worry About Xenetic Biosciences's (NASDAQ:XBIO) Cash Burn Situation
1 year ago | Simply Wall StDid You Manage To Avoid Xenetic Biosciences's (NASDAQ:XBIO) 97% Share Price Wipe Out?
1 year ago | Simply Wall StIs Xenetic Biosciences, Inc. (NASDAQ:XBIO) A Financially Sound Company?
Is Xenetic Biosciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate XBIO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate XBIO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: XBIO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: XBIO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate XBIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: XBIO is good value based on its PB Ratio (0.9x) compared to the US Biotechs industry average (3.6x).
How is Xenetic Biosciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: XBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: XBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: XBIO's revenue (43.2% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: XBIO's revenue (43.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XBIO's Return on Equity is forecast to be high in 3 years time
How has Xenetic Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XBIO is currently unprofitable.
Growing Profit Margin: XBIO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 26.8% per year.
Accelerating Growth: Unable to compare XBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.8%).
Return on Equity
High ROE: XBIO has a negative Return on Equity (-137.38%), as it is currently unprofitable.
How is Xenetic Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: XBIO's short term assets ($8.0M) exceed its short term liabilities ($788.5K).
Long Term Liabilities: XBIO has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: XBIO is debt free.
Reducing Debt: XBIO has no debt compared to 5 years ago when its debt to equity ratio was 61.9%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XBIO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: XBIO has less than a year of cash runway if free cash flow continues to grow at historical rates of 14.1% each year.
What is Xenetic Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XBIO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of XBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jeff Eisenberg (54 yo)
Mr. Jeffrey F. Eisenberg, also known as Jeff, Esq., has been the Chief Executive Officer of Xenetic Biosciences, Inc. since October 26, 2017; has been its Director since July 11, 2016 and also serves as it...
CEO Compensation Analysis
Compensation vs Market: Jeff's total compensation ($USD602.65K) is about average for companies of similar size in the US market ($USD561.50K).
Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.
|CEO, President & Director||3.17yrs||US$602.65k||no data|
|CFO, COO & Corporate Secretary||3.67yrs||US$387.82k||0% |
|Chief Scientific Officer||3.92yrs||US$383.79k||0% |
Experienced Management: XBIO's management team is considered experienced (3.7 years average tenure).
|CEO, President & Director||3.17yrs||US$602.65k||no data|
|Independent Chairman of the Board||no data||US$80.42k||0% |
|Independent Director||4.83yrs||US$80.42k||0% |
|Independent Director||6.92yrs||US$80.42k||0% |
|Independent Director||3.33yrs||US$80.42k||0% |
|Director||3.33yrs||no data||1.49% |
|Member of Scientific Advisory Board||8.25yrs||no data||no data|
|Member of Scientific Advisory Board||1.58yrs||no data||no data|
|Member of Scientific Advisory Board||1.92yrs||no data||no data|
|Independent Director||1.42yrs||US$52.09k||2.97% |
|Independent Non-Executive Director||1.25yrs||no data||no data|
|Member of Scientific Advisory Board||0.83yr||no data||no data|
Experienced Board: XBIO's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.
Xenetic Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Xenetic Biosciences, Inc.
- Ticker: XBIO
- Exchange: NasdaqCM
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$7.304m
- Shares outstanding: 6.30m
- Website: https://www.xeneticbio.com
Number of Employees
- Xenetic Biosciences, Inc.
- 40 Speen Street
- Suite 102
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|XBIO||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jan 2014|
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor n...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/03 00:17|
|End of Day Share Price||2020/12/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.